uniQure N.V. (QURE)
Nasdaq: QURE · Pharmaceutical Preparations · Amsterdam · filing with the SEC since 2013
Who owns uniQure N.V.
As filed with the SECHolders of 5% or more
3
Avoro Capital Advisors LLC holds 9.87% of Ordinary Shares, par value EUR0.05 per share, as its SCHEDULE 13G/A filed Feb 17, 2026 says.
Directors and officers
12
report now, of 28 people on the record since 2017. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Avoro Capital Advisors LLC
SCHEDULE 13G/A · filed Feb 17, 2026 · Ordinary Shares, par value EUR0.05 per share · 6.6% in Aug 14, 2025
JPMorgan Chase & Co.
SCHEDULE 13G/A · filed Oct 16, 2026 · Ordinary Shares, par value 0.05 · 7% in Jul 16, 2026
RTW Investments, LP
SCHEDULE 13G · filed Aug 14, 2026 · Ordinary Shares, par value 0.05 euro · 4.1% in May 15, 2026
G1 Execution Services, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Ordinary Shares, EUR 0.05 par value per share · reported falling below 5%, from 5.7% in Feb 13, 2026
Aberdeen Group plc
SCHEDULE 13G/A · filed Jul 20, 2026 · Ordinary Shares, par value(euro)0.05 per share · reported falling below 5%, from 8.49% in Apr 30, 2026
Nantahala Capital Management, LLC
SCHEDULE 13G/A · filed Aug 14, 2025 · Ordinary Shares, par value EUR 0.05 · reported falling below 5%, from 6.12% in Nov 14, 2024
State Street Corporation
SCHEDULE 13G · filed May 12, 2026 · COMMON STOCK · reported falling below 5%, from 5.2% in Feb 9, 2026
Fmr LLC
SCHEDULE 13G/A · filed May 6, 2026 · COMMON STOCK · reported falling below 5%, from 9.8% in Nov 5, 2025
Vestal Point Capital, LP
SCHEDULE 13G/A · filed Nov 14, 2025 · Ordinary Shares, par value 0.05 euro per share · reported falling below 5%, from 6.8% in Aug 14, 2025
EcoR1 Capital, LLC
SCHEDULE 13G/A · filed Feb 17, 2026 · Ordinary Shares, par value(euro)0.05 per share · reported falling below 5%, from 7.5% in Dec 17, 2024
What QURE reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
uniQure France
A company bought · acquisition · owns, named in the 10-K filed Mar 2, 2026
5 subsidiaries in 4 countries, from the list filed with the 10-K filed Mar 2, 2026.
Insider tradesForm 4
53sales
0purchases
34sales on a scheduled plan
12people selling
$20.2Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 10, 2025 to Nov 10, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 10, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window12 of 30 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Kapusta Matthew C | CEO, Managing Director | 16 | $12.9M | 13 | 0 | $0 |
| Abi-Saab Walid | Chief Medical Officer | 7 | $2.6M | 4 | 0 | $0 |
| Kaye Jack | director | 6 | $1.5M | 5 | 0 | $0 |
| Gut Robert | Chief Medical Officer | 7 | $900,000 | 7 | 0 | $0 |
| Balachandran Madhavan | director | 5 | $900,000 | 4 | 0 | $0 |
| Klemt Christian | Chief Financial Officer | 3 | $400,000 | 0 | 0 | $0 |
| O'Keefe Kylie | Chief Customer & Strat Officer | 1 | $400,000 | 0 | 0 | $0 |
| Potts Jeannette | Chief Legal Officer | 3 | $300,000 | 0 | 0 | $0 |
| Meek David D. | director | 2 | $200,000 | 1 | 0 | $0 |
| Jacques Rachelle Suzanne | director | 1 | $100,000 | 0 | 0 | $0 |
| Post Leonard E | director | 1 | $100,000 | 0 | 0 | $0 |
| Springhorn Jeremy P. | director | 1 | $100,000 | 0 | 0 | $0 |